Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Salivary Gland Neoplasms 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Mesothelioma, Malignant 2Head and Neck Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 2Brenner Tumor 2Adenocarcinoma 1

Interventions

Oxaliplatin 46Gemcitabine 45Fluorouracil 40Capecitabine 31pembrolizumab 30Leucovorin 29Docetaxel 27Cisplatin 25Paclitaxel 23Irinotecan 18Carboplatin 18Bevacizumab 18130-nm albumin-bound paclitaxel 17Radiotherapy 16Pemetrexed 15Albumin-Bound Paclitaxel 15Nivolumab 13Ramucirumab 11Cyclophosphamide 11Drug Therapy 9Trastuzumab 8Erlotinib Hydrochloride 8zolbetuximab 7Taxes 7Radiosurgery 7trastuzumab deruxtecan 6cemiplimab 6Blood Specimen Collection 6regorafenib 5durvalumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma × SS1(dsFv)PE38 × Clear all
NCT01051934 2017-07-02

A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
2 enrolled
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡